ATE554075T1 - Bei mit mtor-kinase und/oder pi3k in zusammenhang stehenden krankheiten angewendete morpholinopyrimidinderivate - Google Patents
Bei mit mtor-kinase und/oder pi3k in zusammenhang stehenden krankheiten angewendete morpholinopyrimidinderivateInfo
- Publication number
- ATE554075T1 ATE554075T1 AT08776183T AT08776183T ATE554075T1 AT E554075 T1 ATE554075 T1 AT E554075T1 AT 08776183 T AT08776183 T AT 08776183T AT 08776183 T AT08776183 T AT 08776183T AT E554075 T1 ATE554075 T1 AT E554075T1
- Authority
- AT
- Austria
- Prior art keywords
- morpholinopyrimidene
- pi3k
- diseases related
- derivatives used
- mtor kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94853907P | 2007-07-09 | 2007-07-09 | |
PCT/GB2008/050548 WO2009007750A1 (en) | 2007-07-09 | 2008-07-08 | Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE554075T1 true ATE554075T1 (de) | 2012-05-15 |
Family
ID=39791229
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT08776183T ATE554075T1 (de) | 2007-07-09 | 2008-07-08 | Bei mit mtor-kinase und/oder pi3k in zusammenhang stehenden krankheiten angewendete morpholinopyrimidinderivate |
Country Status (22)
Country | Link |
---|---|
US (1) | US8138183B2 (de) |
EP (1) | EP2176238B1 (de) |
JP (1) | JP5508260B2 (de) |
KR (1) | KR20100042280A (de) |
CN (1) | CN101809002B (de) |
AR (1) | AR070079A1 (de) |
AT (1) | ATE554075T1 (de) |
AU (1) | AU2008273891B2 (de) |
BR (1) | BRPI0814688A2 (de) |
CA (1) | CA2692720A1 (de) |
CL (1) | CL2008003940A1 (de) |
CO (1) | CO6251364A2 (de) |
CR (1) | CR11200A (de) |
DO (1) | DOP2010000012A (de) |
EA (1) | EA018708B1 (de) |
EC (1) | ECSP109935A (de) |
ES (1) | ES2385692T3 (de) |
HK (1) | HK1142906A1 (de) |
NI (1) | NI201000002A (de) |
PE (1) | PE20100138A1 (de) |
WO (1) | WO2009007750A1 (de) |
ZA (1) | ZA200909224B (de) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008273889B2 (en) * | 2007-07-09 | 2012-03-08 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
JP5599783B2 (ja) | 2008-05-30 | 2014-10-01 | アムジエン・インコーポレーテツド | Pi3キナーゼの阻害薬 |
WO2010103094A1 (en) | 2009-03-13 | 2010-09-16 | Cellzome Limited | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
NZ597579A (en) | 2009-07-02 | 2013-06-28 | Sanofi Sa | Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors |
JP5680639B2 (ja) | 2009-07-02 | 2015-03-04 | サノフイ | 新規6−モルホリン−4−イル−ピリミジン−4−(3h)−オン誘導体、およびakt(pkb)リン酸化阻害剤としてのこの医薬調製物 |
AU2010313152A1 (en) | 2009-10-30 | 2012-04-19 | Ariad Pharmaceuticals, Inc. | Methods and compositions for treating cancer |
UA110697C2 (uk) | 2010-02-03 | 2016-02-10 | Сігнал Фармасьютікалз, Елелсі | ЗАСТОСУВАННЯ ІНГІБІТОРІВ TOR-КІНАЗИ ДЛЯ ЛІКУВАННЯ ПУХЛИННИХ ЗАХВОРЮВАНЬ У ПАЦІЄНТА ЗІ ЗНИЖЕНИМ РІВНЕМ БІЛКА pAMPK ТА/АБО АКТИВНОСТІ AMPK |
EP2542536B1 (de) | 2010-03-04 | 2015-01-21 | Cellzome Limited | Morpholinsubstituierte Harnstoff-Derivate als mTOR-Hemmer |
JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
PL2658844T3 (pl) | 2010-12-28 | 2017-04-28 | Sanofi | Nowe pochodne pirymidyn, ich wytwarzanie i ich zastosowanie farmaceutyczne jako inhibitorów fosforylacji AKT(pkb) |
JP2014510122A (ja) | 2011-04-04 | 2014-04-24 | セルゾーム リミテッド | mTOR阻害剤としてのジヒドロピロロピリミジン誘導体 |
CN103517707A (zh) | 2011-04-29 | 2014-01-15 | 西莱克塔生物科技公司 | 从合成纳米载体中控制释放免疫抑制剂 |
CA2843887A1 (en) | 2011-08-03 | 2013-02-07 | Signal Pharmaceuticals, Llc | Identification of gene expression profile as a predictive biomarker for lkb1 status |
CN103917530B (zh) | 2011-09-21 | 2016-08-24 | 塞尔佐姆有限公司 | 作为mtor抑制剂的吗啉代取代的脲或氨基甲酸衍生物 |
WO2013049250A1 (en) | 2011-09-27 | 2013-04-04 | Amgen Inc. | Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer |
CN103946222B (zh) | 2011-10-07 | 2016-12-28 | 塞尔佐姆有限公司 | 作为mtor抑制剂的吗啉代取代的双环嘧啶脲或氨基甲酸衍生物 |
FR2994572B1 (fr) * | 2012-08-17 | 2015-04-17 | Centre Nat Rech Scient | Pyrido[3,2-d]pyrimidines trisubstituees, leurs procedes de preparation et leurs utilisation en therapeutique |
AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
AU2014219075C1 (en) * | 2013-02-19 | 2018-09-06 | Amgen Inc. | Cis-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
WO2014151863A1 (en) | 2013-03-14 | 2014-09-25 | Amgen Inc. | Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer |
TW201521725A (zh) | 2013-04-17 | 2015-06-16 | Signal Pharm Llc | 使用tor激酶抑制劑組合療法以治療癌症之方法 |
JP6382948B2 (ja) | 2013-04-17 | 2018-08-29 | シグナル ファーマシューティカルズ,エルエルシー | 癌を治療するためのtorキナーゼ阻害剤及びシチジン類似体を含む組合せ療法 |
PE20160041A1 (es) | 2013-04-17 | 2016-01-28 | Signal Pharm Llc | FORMULACIONES FARMACEUTICAS, PROCESO, FORMAS SOLIDAS Y METODOS DE USO RELACIONADOS CON 1-ETIL-7-(2-METIL-6-(1H-1,2,4-TRIAZOL-3-IL)PIRIDIN-3-IL)-3,4-DIHIDROPIRAZINO[2,3-b]PIRAZIN-2(1H)-ONA |
US9937169B2 (en) | 2013-04-17 | 2018-04-10 | Signal Pharmaceuticals, Llc | Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy |
EP2986322A1 (de) | 2013-04-17 | 2016-02-24 | Signal Pharmaceuticals, LLC | Kombinationstherapie mit einem tor-kinaseinhibitor und einer 5-substituierten chinazolinonverbindung zur behandlung von krebs |
CA2908830C (en) | 2013-04-17 | 2021-12-07 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
TWI631950B (zh) | 2013-04-17 | 2018-08-11 | 標誌製藥公司 | 藉二氫吡𠯤并吡𠯤治療癌症 |
KR20220025909A (ko) | 2013-05-03 | 2022-03-03 | 셀렉타 바이오사이언시즈, 인크. | 면역 관용의 유도를 위한 특정된 약역학적 유효 수명을 갖는 면역억제제 및 항원의 전달 |
EP3003313A1 (de) | 2013-05-29 | 2016-04-13 | Signal Pharmaceuticals, LLC | Pharmazeutische zusammensetzungen von (7- (6-)2-hydroxypropan-2-yl pyridin-3-yl)-1-(trans-)4-methoxycyclohexyl-)3,4-dihydropyrazin[2,3-b-]pyrazin-2-(1h-)on, feste form daraus und verfahren zu deren verwendung |
JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
WO2015101586A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
JP2017511367A (ja) | 2014-04-16 | 2017-04-20 | シグナル ファーマシューティカルズ,エルエルシー | 1−エチル−7−(2−メチル−6−(1H−1,2,4−トリアゾール−3−イル)ピリジン−3−イル)−3,4−ジヒドロピラジノ[2,3−b]ピラジン−2(1H)−オン及び共形成物を含む固体形態、その組成物及び使用方法 |
MX2016015280A (es) * | 2014-06-26 | 2017-03-03 | Hoffmann La Roche | Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso. |
PE20170682A1 (es) | 2014-08-04 | 2017-06-15 | Nuevolution As | Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados utiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncologicas y autoinmunitarias |
BR112017001470A2 (pt) | 2014-09-07 | 2018-02-20 | Selecta Biosciences Inc | métodos e composições para atenuar as respostas imunes do vetor de transferência anti-viral de terapia genética |
TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
CN110612122A (zh) | 2017-03-11 | 2019-12-24 | 西莱克塔生物科技公司 | 与用抗炎剂和包含免疫抑制剂之合成纳米载体进行的组合治疗相关的方法和组合物 |
WO2018218197A2 (en) | 2017-05-26 | 2018-11-29 | Board Of Regents, The University Of Texas System | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase |
CN110996955A (zh) | 2017-06-22 | 2020-04-10 | 细胞基因公司 | 以乙型肝炎病毒感染为特征的肝细胞癌的治疗 |
LT3651768T (lt) | 2017-07-13 | 2024-04-25 | Board Of Regents, The University Of Texas System | Heterocikliniai atr kinazės inhibitoriai |
US10800774B2 (en) | 2017-08-17 | 2020-10-13 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of ATR kinase |
CN112218631B (zh) | 2018-03-16 | 2023-12-22 | 德州大学系统董事会 | Atr激酶的杂环抑制剂 |
EP4076657A1 (de) | 2019-12-20 | 2022-10-26 | Nuevolution A/S | Gegen nukleäre rezeptoren wirksame verbindungen |
US11780843B2 (en) | 2020-03-31 | 2023-10-10 | Nuevolution A/S | Compounds active towards nuclear receptors |
US11613532B2 (en) | 2020-03-31 | 2023-03-28 | Nuevolution A/S | Compounds active towards nuclear receptors |
CN111646985A (zh) * | 2020-06-01 | 2020-09-11 | 江苏集萃分子工程研究院有限公司 | 一种含嘧啶杂环抗肿瘤药物分子azd6738的合成方法 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3922735A1 (de) | 1989-07-11 | 1991-01-24 | Hoechst Ag | Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide |
DE60144322D1 (de) | 2000-04-27 | 2011-05-12 | Astellas Pharma Inc | Kondensierte heteroarylderivate |
JP3810017B2 (ja) * | 2000-04-27 | 2006-08-16 | アステラス製薬株式会社 | 縮合ヘテロアリール誘導体 |
ATE340784T1 (de) | 2000-11-10 | 2006-10-15 | Hoffmann La Roche | Pyrimidinderivate und deren verwendung als neuropeptid-y-rezeptorliganden |
ATE527250T1 (de) | 2002-11-21 | 2011-10-15 | Novartis Ag | 2,4,6-trisubstituierten pyrimidinen als phosphotidylinositol (pi) 3-kinase inhibitoren und deren verwendung zur behandlung von krebs |
EP1626725A4 (de) | 2003-05-29 | 2006-06-14 | Synta Pharmaceuticals Corp | Heterocyclische verbindungen zur prävention und behandlung von störungen in verbindung mit übermässigem knochenschwund |
GB0415365D0 (en) * | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
GB0415367D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
GB0415364D0 (en) * | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
WO2007084413A2 (en) | 2004-07-14 | 2007-07-26 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
JP2008519850A (ja) * | 2004-11-10 | 2008-06-12 | シンタ ファーマシューティカルズ コーポレーション | Il−12調節化合物 |
WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
TW200720256A (en) | 2005-05-13 | 2007-06-01 | Synta Pharmaceuticals Corp | IL-12 modulatory compounds |
CA2608726C (en) | 2005-05-20 | 2013-07-09 | Methylgene Inc. | Inhibitors of vegf receptor and hgf receptor signaling |
DE102005024494A1 (de) | 2005-05-27 | 2006-11-30 | Bayer Healthcare Ag | Verwendung von Cyanopyrimidinen |
WO2007005673A1 (en) | 2005-07-01 | 2007-01-11 | Irm Llc | Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors |
EP1911753A1 (de) | 2005-07-29 | 2008-04-16 | Takeda Pharmaceutical Company Limited | Spirocyclische verbindung |
BRPI0615781A2 (pt) | 2005-09-01 | 2009-06-16 | Array Biopharma Inc | compostos inibidores de raf e métodos de uso destes |
JP2007091649A (ja) | 2005-09-29 | 2007-04-12 | Taisho Pharmaceut Co Ltd | ピリミジン誘導体及びその使用に関連する治療方法 |
JP4531027B2 (ja) | 2005-09-29 | 2010-08-25 | 田辺三菱製薬株式会社 | 医薬組成物 |
WO2007041358A2 (en) | 2005-09-30 | 2007-04-12 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
ES2401192T3 (es) | 2005-09-30 | 2013-04-17 | Vertex Pharmceuticals Incorporated | Deazapurinas útiles como inhibidores de janus cinasas |
GB0520657D0 (en) | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
GB2431156A (en) * | 2005-10-11 | 2007-04-18 | Piramed Ltd | 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase |
DK1945631T3 (da) | 2005-10-28 | 2012-10-22 | Astrazeneca Ab | 4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer |
EP1970375A4 (de) | 2005-11-29 | 2010-06-02 | Toray Industries | Arylmethylenharnstoffderivate und anwendung davon |
GB0525080D0 (en) | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
GB0525081D0 (en) | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
GB0525083D0 (en) * | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
NL2000323C2 (nl) | 2005-12-20 | 2007-11-20 | Pfizer Ltd | Pyrimidine-derivaten. |
JP2009523161A (ja) * | 2006-01-11 | 2009-06-18 | アストラゼネカ アクチボラグ | モルホリノピリミジン誘導体と療法におけるその使用 |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
EA200870217A1 (ru) | 2006-01-30 | 2009-02-27 | Экселиксис, Инк. | 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции |
WO2007105023A1 (en) | 2006-03-15 | 2007-09-20 | Csir | Modulation of phosphoryl transferase activity of glutamine synthetase |
JP5243696B2 (ja) | 2006-03-17 | 2013-07-24 | 田辺三菱製薬株式会社 | ベンゼン誘導体 |
US8044068B2 (en) | 2006-04-04 | 2011-10-25 | Taisho Pharmaceutical Co., Ltd | Aminopyrrolidine compound |
US20070293491A1 (en) | 2006-04-19 | 2007-12-20 | Novartis Vaccines And Diagnostics, Inc. | Indazole compounds and methods for inhibition of cdc7 |
JP5225076B2 (ja) | 2006-04-27 | 2013-07-03 | 田辺三菱製薬株式会社 | チアゾール環を含むカルボン酸誘導体の医薬用途 |
GB0610909D0 (en) | 2006-06-05 | 2006-07-12 | Merck Sharp & Dohme | Therapeutic treatment |
US8222256B2 (en) | 2006-07-05 | 2012-07-17 | Exelixis, Inc. | Methods of using IGFIR and ABL kinase modulators |
CA2660758A1 (en) * | 2006-08-24 | 2008-02-27 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
JP2010501537A (ja) * | 2006-08-24 | 2010-01-21 | アストラゼネカ アクチボラグ | 増殖性障害の治療に有用なモルホリノピリミジン誘導体 |
US20080234262A1 (en) * | 2007-03-21 | 2008-09-25 | Wyeth | Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors |
WO2008125833A1 (en) | 2007-04-12 | 2008-10-23 | Piramed Limited | Pharmaceutical compounds |
EP2176256A2 (de) | 2007-07-09 | 2010-04-21 | AstraZeneca AB | Trisubstituierte pyrimidinderivate zur behandlung proliferativer krankheiten |
-
2008
- 2008-07-08 AT AT08776183T patent/ATE554075T1/de active
- 2008-07-08 CA CA 2692720 patent/CA2692720A1/en not_active Abandoned
- 2008-07-08 US US12/668,056 patent/US8138183B2/en not_active Expired - Fee Related
- 2008-07-08 EA EA201000091A patent/EA018708B1/ru not_active IP Right Cessation
- 2008-07-08 KR KR1020107002942A patent/KR20100042280A/ko not_active Application Discontinuation
- 2008-07-08 WO PCT/GB2008/050548 patent/WO2009007750A1/en active Application Filing
- 2008-07-08 JP JP2010515602A patent/JP5508260B2/ja not_active Expired - Fee Related
- 2008-07-08 AU AU2008273891A patent/AU2008273891B2/en not_active Ceased
- 2008-07-08 CN CN2008801062258A patent/CN101809002B/zh not_active Expired - Fee Related
- 2008-07-08 BR BRPI0814688A patent/BRPI0814688A2/pt not_active IP Right Cessation
- 2008-07-08 ES ES08776183T patent/ES2385692T3/es active Active
- 2008-07-08 EP EP08776183A patent/EP2176238B1/de active Active
- 2008-12-19 PE PE2008002157A patent/PE20100138A1/es not_active Application Discontinuation
- 2008-12-30 CL CL2008003940A patent/CL2008003940A1/es unknown
- 2008-12-30 AR ARP080105784A patent/AR070079A1/es unknown
-
2009
- 2009-12-23 ZA ZA2009/09224A patent/ZA200909224B/en unknown
-
2010
- 2010-01-08 DO DO2010000012A patent/DOP2010000012A/es unknown
- 2010-01-08 NI NI201000002A patent/NI201000002A/es unknown
- 2010-01-08 CR CR11200A patent/CR11200A/es not_active Application Discontinuation
- 2010-02-03 EC EC2010009935A patent/ECSP109935A/es unknown
- 2010-02-09 CO CO10014081A patent/CO6251364A2/es not_active Application Discontinuation
- 2010-10-04 HK HK10109461.9A patent/HK1142906A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2008273891A1 (en) | 2009-01-15 |
CR11200A (es) | 2010-06-17 |
PE20100138A1 (es) | 2010-03-20 |
US20100249131A1 (en) | 2010-09-30 |
JP5508260B2 (ja) | 2014-05-28 |
CA2692720A1 (en) | 2009-01-15 |
CL2008003940A1 (es) | 2010-09-24 |
CO6251364A2 (es) | 2011-02-21 |
ES2385692T3 (es) | 2012-07-30 |
AR070079A1 (es) | 2010-03-10 |
BRPI0814688A2 (pt) | 2017-06-06 |
CN101809002A (zh) | 2010-08-18 |
EA018708B1 (ru) | 2013-10-30 |
ZA200909224B (en) | 2011-05-25 |
EP2176238A1 (de) | 2010-04-21 |
AU2008273891B2 (en) | 2012-01-12 |
NI201000002A (es) | 2010-10-12 |
JP2010533160A (ja) | 2010-10-21 |
ECSP109935A (es) | 2010-03-31 |
HK1142906A1 (en) | 2010-12-17 |
DOP2010000012A (es) | 2010-01-31 |
EA201000091A1 (ru) | 2010-06-30 |
WO2009007750A1 (en) | 2009-01-15 |
CN101809002B (zh) | 2013-03-27 |
EP2176238B1 (de) | 2012-04-18 |
KR20100042280A (ko) | 2010-04-23 |
US8138183B2 (en) | 2012-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE554075T1 (de) | Bei mit mtor-kinase und/oder pi3k in zusammenhang stehenden krankheiten angewendete morpholinopyrimidinderivate | |
HK1253532A1 (zh) | 用於治療變應性、炎性和感染性疾病的嘌呤衍生物 | |
BRPI0817681A2 (pt) | Compostos de tienopirimidina e pirazolopirimidina e seu uso como inibidores de mtor quinase e pi3 quinase | |
ZA201101105B (en) | Purine derivatives for use in the treatment of allergic,inflammatory and infectious diseases | |
IL193230A (en) | Use of benzoxoborol derivatives in the preparation of drugs for the treatment of inflammatory diseases | |
ZA201000075B (en) | Purin derivatives for use in the treatment of fab-related diseases | |
BR112012031194A2 (pt) | derivados de cisteamina e seu uso no tratamento de ehna | |
DE602005022116D1 (de) | 5-heteroarylthiazole und deren verwendung als pi3k-inhibitoren | |
BRPI1011066A2 (pt) | "pirazolopirimidinas e heterociclos relacionados como inibidores de quinase | |
HK1153926A1 (en) | Purin derivatives for use in the treatment of fab-related diseases fab- | |
BRPI0810094A2 (pt) | Inibidores de kinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas | |
CO6950473A2 (es) | Novedosos derivados de purina y su uso en el tratamiento de enfermedades | |
IL210055A0 (en) | Thiophene or thiazole derivatives and their use as pi3k inhibitors | |
BRPI0921156A2 (pt) | inibidores de pi3k/mtor quinase | |
BR112012001344A2 (pt) | derivados de 17hidróxi-17-pentafluoroetil-estra-4,9(10)-dieno-11-arila, método de produção destes e uso destes para o tratamento de doenças | |
IL195900A0 (en) | Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases | |
IL206690A0 (en) | Protein kinase inhibitors and their use in the preparation of medicaments | |
DK3211005T3 (da) | Terapeutisk anvendelse af specifik ligand i msrv-associerede sygdomme | |
HK1148271A1 (zh) | -苄基- -羥基甲基吲唑衍生物及其在治療基於 表達的疾病中的用途 | |
DE602008001981D1 (de) | Stellung und therapeutische verwendung | |
BRPI0717774A2 (pt) | Tratamento de hiperbilirrubinemia em recém-nascidos que utiliza baixas dosagens de estansoporfina | |
BRPI0817044A2 (pt) | Compostos de nicotinamida substituída e seu uso em medicamentos | |
BRPI0714318A2 (pt) | Utilização de 2-benzoil-imidazopiridinas em terapêutica | |
DK2293846T3 (da) | Depsipeptider og deres terapeutiske anvendelse | |
BRPI0811572A2 (pt) | Uso de compostos imunomoduladores no tratamento de doenças alérgicas |